Vertex Pharmaceuticals

Vertex Pharmaceuticals is a biotechnology company that has built a dominant franchise in treatments for cystic fibrosis, where its therapies are the standard of care for most patients. Building on that foundation, it is expanding into new areas such as pain, kidney disease and cell-based therapies, backed by a strong research pipeline and substantial cash reserves. Vertex pays no dividend, choosing instead to reinvest its considerable profits into research, clinical trials and acquisitions as it seeks to diversify beyond cystic fibrosis. It is a growth-oriented biotech, and the absence of a payout is consistent with that strategy. Investors here are backing pipeline success and earnings growth rather than any current income.